As boundaries between AML and MDS fade in current classifications [38], recent data indicate that TP53-mutated AML and MDS with excess blasts share similar characteristics and prognoses, suggesting they should be regarded as a specific molecular disease entity [112,113,114]. The gene discussed is TP53; the disease is acute myeloid leukemia.